Pregnancy and Lactation
Long usage in clinical studies have shown that no teratogenic hazards are associated with sulfasalazine.
The amount of sulfasalazine that passes into the milk is negligible.
The concentration of sulfapyridine in the mother’s milk is about 40% of that in serum. However, the risk of kernicterus in healthy suckling children has been assessed as low at therapeutic doses, since sulfapyridine has been shown to have a poor bilirubin displacing capacity.
